Gemtuzumab Ozogamicin as Part of Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed Acute Myeloid Leukemia-Reference-Cited by-同舟云学术

Gemtuzumab Ozogamicin as Part of Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed Acute Myeloid Leukemia

Published:2008-09-01 Issue:17 Volume:14 Page:5585-5593
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Bornhäuser Martin,Illmer Thomas,Oelschlaegel Uta,Schetelig Johannes,Ordemann Rainer,Schaich Markus,Hänel Mathias,Schuler Ulrich,Thiede Christian,Kiani Alexander,Platzbecker Uwe,Ehninger Gerhard

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Worked to the bone: antibody-based conditioning as the future of transplant biology;Journal of Hematology & Oncology;2022-05-19

2. Thrombopoietin accumulation in hepatocytes induces a decrease in its serum levels in a sinusoidal obstruction syndrome model;Molecular Medicine Reports;2022-04-26

3. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults;Expert Opinion on Biological Therapy;2020-10-05

4. Gemtuzumab ozogamicin monotherapy prior to stem cell infusion induces sustained remission in a relapsed acute myeloid leukemia patient after allogeneic stem cell transplantation;Medicine;2020-08-28

5. Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis;Biology of Blood and Marrow Transplantation;2020-05